AXL is altered in 3.85% of hepatoblastoma patients [2].

AXL is an inclusion eligibility criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and hepatoblastoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and hepatoblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and hepatoblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MET is an inclusion eligibility criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and hepatoblastoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and hepatoblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RET is an inclusion eligibility criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and hepatoblastoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and hepatoblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and hepatoblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TET2 is altered in 7.69% of hepatoblastoma patients [2].

TET2 is an inclusion eligibility criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and hepatoblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].